chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report was received from a registered nurse referring to her 3.5 year old daughter. The patient's medical history, concurrent conditions and concomitant therapies were not reported. It was reported that the patient was not pregnant. On an unknown date in the past, the patient had an episode of pink eye, which was treated with eye drops that contained NEOSPORIN, and she had reactions to the eye drops (red spots and trouble breathing), which were treated by her mother with BENADRYL. Likewise, the patient's mother felt that she had used neomycin ointment on her daughter in the past but not sure if daughter had a reaction to that. On 07-NOV-2015, the patient was vaccinated with a first dose of VARIVAX (lot # 1010146; strength, dose, route, anatomical location and expiration date were not provided), for prophylaxis. On an unknown date, after receiving a dose of VARIVAX, every time that the patient got sick, had a cold or got a virus, she experienced chicken pox, clarified as red bumps. The registered nurse reported that her daughter got one or two bumps on groin, belly and maybe neck. It was also reported that the patient's physician stated that the bumps look like a bug bite. In addition, on an unspecified day in June 2018 (reported as this week), the patient got the bumps on the neck, abdomen and groin, that look scabbed over and there were 30 to 50 bumps and this time the bumps were itchy. Therefore, an unspecified culture showed a came back of negative bacterial. Moreover, the patient's mother was waiting for results of viral culture from patient's pediatrician. On an unknown day in July 2018 (reported as next month), the patient had an appointment with an allergist. In addition, the patient's mother was wondering if there was any relationship to neomycin in VARIVAX to episodic rashes that daughter was experiencing. The registered nurse was not sure if the patient should have received the second recommended dose of VARIVAX. The patient's mother felt certain that those rashes were repeated bouts of breakthrough varicella. It was also reported that on an unspecified date, the patient had episode of a respiratory illness, which was treated with inhaled corticoid steroids. At the time of reporting, the outcome of varicella, viral infection, nasopharyngitis, malaise and respiratory disorder was unknown. The causal relationship between varicella, viral infection, nasopharyngitis, malaise, rash and respiratory disorder with the VARIVAX was not reported. Lot number 1010146 is an invalid lot number for varicella virus vaccine live (oka/merck).
Fatigue, Nausea, Diarrhea, Vomiting, headache
Began having chills; Low grade fever of 100.2F; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (Began having chills) and PYREXIA (Low grade fever of 100.2F) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Spinal operation (Spinal surgery 5 weeks ago).    On 10-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Apr-2021, the patient experienced CHILLS (Began having chills) and PYREXIA (Low grade fever of 100.2F). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, CHILLS (Began having chills) and PYREXIA (Low grade fever of 100.2F) had not resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication information not provided.
Swelling and pain went away; This spontaneous case was reported by a consumer and describes the occurrence of THERAPEUTIC RESPONSE UNEXPECTED (Swelling and pain went away) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 020F21A, 010A21A and 018B21A) for COVID-19 vaccination.     The patient's past medical history included Joint pain (Joint pain in the past) and Joint swelling (Joint swelling in the past). Concurrent medical conditions included Osteoarthritis, Psoriatic arthritis and Alopecia. Concomitant products included METHOTREXATE for an unknown indication.   On 28-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 31-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced THERAPEUTIC RESPONSE UNEXPECTED (Swelling and pain went away). At the time of the report, THERAPEUTIC RESPONSE UNEXPECTED (Swelling and pain went away) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information details were reported.   This case was linked to MOD-2022-496953, MOD-2021-079053, MOD-2022-496962 (Patient Link).
Information has been received from a pharmacist referring to a patient of unknown age and gender. The patient's concurrent conditions, concomitant medication and medical history were not provided. On 25-JAN-2016 the patient was inadvertently vaccinated with an expired dose of ZOSTAVAX (lot # J001698, expiry date 08-MAY-2014, dose, route and dose number were unspecified). Product quality complaint (PQC) was filed for mismatched lot number and expiration date on the ZOSTAVAX vial and carton. No adverse effect was reported. Additional information has been requested.
Pain and swelling in my lymph node in left armpit; Pain and swelling in my lymph node in left armpit; On 30Jan2021, the patient received the second dose BNT162B2 and first dose was received on 13Jan2021; This is a spontaneous report from a contactable consumer (patient). A 43-year-old female patient received the second dose of bnt162b2 (Pfizer-Biontech COVID-19 Vaccine, Lot number: EL8982), via an unspecified route of administration at the left arm on 30Jan2021 at a single dose for covid-19 immunization. The vaccine was administered in a hospital. The patient has no other medical history. There were no concomitant medications. The patient was not pregnant at the time of vaccination. Historical vaccine includes 1st dose of BNT162B2 for COVID-19 immunization, on 13Jan2021 12:00PM at the left arm, lot number: EL3246 at the age of 43 years. On 30Jan2021, the patient received the second dose BNT162B2 and first dose was received on 13Jan2021. On 01Feb2021 06:00 AM, the patient experienced pain and swelling in her lymph node in left armpit. The events were assessed as non-serious, did not result in death, not life threatening, did not cause/prolonged hospitalization, not disabling/incapacitating, did not cause congenital anomaly/birth defect. Treatment was not received for the adverse events. The patient has not received any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination the patient has not been tested for COVID-19. The events pain and swelling in my lymph node in left armpit recovered on Feb2021.  No follow-up attempts are possible. No further information is expected.
This gentleman came in to get his second COVID-19 vaccine. The appointment was scheduled as a second dose for Moderna. I had asked him if he was here for second dose of Moderna. No conflict was noted at the time. I did not get his card from him until afterwards, so I did not see what his first dose was- I just went off of the scheduled appointment. After he left he had called the facility and stated his first dose was Pfizer. I looked in our system, noticing he has three different accounts. I told him I would check with agency to see if there was anything I needed to do about it. I called him back after agency had contacted me back to let him know the information I received. I let him know that we would not repeat another dose at this time and that he would still be considered fully vaccinated  against COVID-19 ?2 weeks after receipt of the second dose of an mRNA vaccine.
Vaccines administered 1/26/06. Exactly seven days later child woke up in night around 11 pm with cough that sounded like he was trying to constantly clear his throat. Awoke next morning with white spots on face and back/body but had red, raised areas on back, but not past the waist. Eyes, nose, and lips were swollen. Taken to ER. Given oral steroid at ER. Mom states she gave him more oral steroid at home as doctor ordered. Complete recovery and no further treatment needed. Mom informed nurse of reaction at 15 month visit on 5/10/2006.
Patient is a 57 y.o. female patient of, MD with a history of SOB   Discharge Diagnoses:   1. COVID PNA, symptoms 2/20, +2/24: -CT chest negative PE, mild mucous plugging, multifocal pneumonia -Home Eliquis DVT prophylaxis -Decadron completed    2.  Acute hypoxic respiratory failure: with post-infective bronchospasm due to recent COVID -remains on room air with satisfactory o2 sats - nebulizer set up for home    3.  AKI, hyponatremia: -resolved    4. Pulmonary nodules: -visualized on CT chest, noncalcified granulomas vs metastatic disease -pulm consulted   5. Hypokalemia; replacement given    5.  Other chronic medical conditions: History of asthma, chronic back pain, history of breast cancer, chronic pain, cognitive developmental delay, CAD, history DVT, depression, history factor V Leiden, hyperlipidemia, hypertension, hypothyroidism, morbid obesity, OSA, port wine stain to face, history of PE, history of renal cell carcinoma, history of seizure, history of stroke, Sturge-Weber disease     Patient was initially admitted to the hospital following COVID symptoms starting February 20.  Patient was discharged on the 27th.  She returned to the ER on 3 March return to the ED was found to have pneumonia initiated on Vanco and Zosyn in ED.  Patient was further evaluated by pulmonary who found on her CT PE study bronchopneumonia.  Discussed nebulizer treatments.  No further treatment necessary for COVID from the 20th   We will discharge to home with a course of doxycycline and have patient follow-up outpatient with her primary care provider; patient agreeable to plan
I experienced an aura in my vision, which then progressed to shaking, and nausea. I had to take lorazepam in multiple doses to get it to resolve.
12:15 Client verbalize tightness with inhalation below the right breast.  Client was evaluated by onsite paramedics and release to go home at 12:27 pm.
Patient states she had redness/swelling at injection site, fever/chills and headache that resolved the next day. She states she has a lump under her left armpit about the size of the end of her thumb. The lump has persisted through today 7/17/19. She has gone to urgent care and will be having an ultrasound of the area today.
Cellulitis at the injection site; Redness at injection site; The injection site that extended over 7 to 8 inches up and down the arm with pain; Flu Like Symptoms; Chills; Fever; Restlessness; Malaise; Itching all over the body; This case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in a 68-year-old female patient who received Herpes zoster (Shingrix) (batch number ZR979, expiry date 28th March 2022) for prophylaxis.   The patient's past medical history included shingles (has shingles in 2000 and 3 months before reporting date). Previously administered products included tetanus vaccine (received on an unknown date), Chickenpx vaccine (received on an unknown date), Measles vaccine (received on an unknown date) and vaccine (childhood vaccine on an unknown date).   On 1st March 2020, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 1st March 2020, less than a day after receiving Shingrix, the patient experienced influenza-like symptoms, chills, fever, restlessness, malaise and generalized pruritus. On 2nd March 2020, the patient experienced injection site cellulitis, injection site erythema and injection site pain. On an unknown date, the outcome of the influenza-like symptoms, chills, fever, restlessness, malaise and generalized pruritus were recovered/resolved and the outcome of the injection site cellulitis, injection site erythema and injection site pain were recovering/resolving.   It was unknown if the reporter considered the influenza-like symptoms, chills, fever, restlessness, malaise, generalized pruritus, injection site cellulitis, injection site erythema and injection site pain to be related to Shingrix.  Additional case details were reported as follows: The patient received her first dose of Shingrix vaccine and experienced flu like symptoms, chills, fever, restlessness, malaise and itching all over the body for 24 hours post vaccination. The patient also experienced cellulitis, redness at the injection site that extended over 7 to 8 inches up and down the arm with pain.  Pain and cellulitis have decreased and the redness has decreased down to 2 cm at the spot of injection. The patient consented to follow up. This case is 1 out of 2 cases reported by the same reporter.
Approximately two weeks after vaccination I noticed his left foot and leg swelling. Patient advised me that he needed to go to the hospital because he was not feeling well and his oxygen level was low.   We called 911 and was taken to the hospital.  After at the hospital I advised a male nurse  that I was concerned about his leg being swollen cause he had been given the Jansen Covid vaccine and I was concerned about blood clots.   Everyday I would tell someone in the hospital (never saw a doctor I could talk to) about his swollen leg but did not really get anyone interested. Before he was moved to a Veteran?s State Home, I overheard someone saying they were going to give him his anticoagulant.  I?m filing this  report in case the swollen leg was a result of blood clots due to the vaccine.
Systemic: Allergic: Difficulty Breathing-Medium, Systemic: Allergic: Difficulty Swallowing, Throat Tightness-Medium, Additional Details: Patient Reported difficulty in breathing after receiving the vaccines. Patient refused administration of Epipen. 911 was called to transport patient to emergency room for treatment.
patient got the flu shot and had bad reactions never again; Initial information was received on 15-Nov-2020 regarding an unsolicited non-valid non-serious case from a consumer (patient) via social media.  This case involves a patient of unknown age who got the flu shot and had bad reactions never again (unevaluable event), while patient was treated with influenza vaccine.  Medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medication was not reported.  On an unknown date, the patient received influenza vaccine [lot number: unknown and expiration date: unknown] at an unknown dose via an unknown route in an unknown administration site for prophylactic vaccination.  On an unknown date (latency: unknown) after starting the suspect vaccine therapy, patient got the flu shot and had bad reactions never again (unevaluable event).  No laboratory data was reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, outcome of the event was unknown.  There will be no information available regarding batch number in this case.
Nausea, vomiting, diarrhea, muscle aches, headache, low grade temp, chills.  Symptoms lasted 24-36 hours.
10 days after varicella immunization developed itchy papule vesicular grouped lesion at right central thigh. (injection site)
This case was reported by a consumer via call center representative and described the occurrence of respiratory tract congestion in a 77-year-old male patient who received SHINGRIX. Concurrent medical conditions included blood pressure high, cardiac arrhythmia and allergy (had drainage from allergies). Concomitant products included NORVASC and PRADAXA. On 10th April 2018, the patient received the 1st dose of SHINGRIX. On 10th April 2018, several hours after receiving SHINGRIX, the patient experienced respiratory tract congestion and cough. In April 2018, the patient experienced coughing blood, moaning, feeling cold, labored respiration and fatigue. On 11th April 2018, the outcome of the moaning and labored respiration were recovered/resolved. On an unknown date, the outcome of the respiratory tract congestion, coughing blood, feeling cold and cough were unknown and the outcome of the fatigue was not recovered/not resolved. The reporter considered the respiratory tract congestion, coughing blood, feeling cold, cough and fatigue to be possibly related to SHINGRIX. It was unknown if the reporter considered the moaning and labored respiration to be related to SHINGRIX. Additional details were reported as follows: This case was reported by the patient's wife. Prior to the vaccination, the patient had some drainage from allergies. At 16:00, the patient received SHINGRIX on an unknown arm. During the night, the patient started coughing and several times had to get up and spit up the congestion. The next day, in the morning, when the patient spit up the congestion, there were blood traces in it. The caller also noted that, instead of the patient's usual snoring, he was moaning in his sleep. Around at 6 AM (14 hours after vaccination), he felt very cold, but when the caller checked patient's temperature at 7 AM, he did not have fever. The patient felt very fatigued and did not want to get up in the morning, which was very unusual for him. He was asleep at the time of the call, so the reporter did not know how the symptoms were progressed, but she did note that, the patient had stopped heavier breathing and moaning he had earlier in the morning.
MMR and Varivax were ordered and I administered Proquad and Varivax
Increased heaviness in monthly menstrual cycles, resulting in severe anemia and fibroids  Partial hysterectomy was performed
Feeling dizzy/light-headed, fainting, then vomiting - happened about 10pm
Injection sight pain; 3 lymph nodes under left arm that are swollen; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of VACCINATION SITE PAIN (Injection sight pain) and LYMPHADENOPATHY (3 lymph nodes under left arm that are swollen) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (Injection sight pain) and LYMPHADENOPATHY (3 lymph nodes under left arm that are swollen). At the time of the report, LYMPHADENOPATHY (3 lymph nodes under left arm that are swollen) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications provided. No treatment.   This case was linked to MOD-2021-010135 (Patient Link).
Pain at the injection site; Just a very mild ache deep in the arm; This is a spontaneous report from a contactable consumer, the patient. A 75-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3246) via an unspecified route of administration in the arm left on 18Jan2021 (at the age of 75-year-old), as a single dose for COVID-19 immunisation. The patient had no relevant medical history. Concomitant medications included losartan 50mg (MANUFACTURER UNKNOWN) and simvastatin 20mg (MANUFACTURER UNKNOWN), both for unknown indication from an unknown date. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18Jan2021, the patient had pain at the injection site since the first shot date. No other reaction at all. Just a very mild ache deep in the arm. It worried the patient that she had an internal ache at the site since first dose. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events pain at the injection site and mild ache deep in the arm were unknown at the time of this report. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Em9810) via an unspecified route of administration in the arm right on 05Feb2021 (at the age of 75-year-old), as a single dose for COVID-19 immunisation.  No follow-up attempts are needed. No further information is expected.
This case was reported by a medical assistant and described the occurrence of joint swelling in a 52 year old female pt who received hep B vaccine recombinant (Engerix B) for prophylaxis. The pt had traveled " in early August 2003" and returned with a pruritic rash. The rash had resolved by 8/5/03. On 8/6/03, the pt received the 1st dose of Engerix B (538A2; not a valid lot number). On 8/9/03, three days post-immunization, the pt experienced swelling in the joints of her hands and ankles and a re-occurrence of the pruritic rash. The pt treated the rash with Benadryl. The pt was seen by the physician on 8/13/03 and 8/15/03. No treatment was given. As of 8/15/03, the events had improved. The Engerix B immunization series was discontinued.
I experienced extreme itching at the injection site about 30 min after the injection. It continued on until the follow day (today). It still itches. At the injection site I have a large red, raised rash approximately 4-5 inches in diameter. It is warm to the touch and feels as though it is burning inside. I feel very lethargic and exhausted and generally very off. I have received the flu shot every year as long as I can remember and have never experienced anything more than slight pain at the injection site.
EXPERIENCE ISSUES; HORRIBLE; WORRIED ABOUT VACCINE MANUFACTURING UNIT; This spontaneous report received from a patient concerned a 47 year old male. The patient's height, and weight were not reported. The patient's past medical history included covid-19 infection, and concurrent conditions included non-smoker, and alcohol use. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 21-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the subject experienced experience issues, horrible, and worried about vaccine manufacturing unit. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the experience issues, horrible and worried about vaccine manufacturing unit was not reported. This report was non-serious. This case, from the same reporter is linked to 20210648458.
Mother states when the child woke up the next day 8/19/2017 there were hives over her body and she had a fever. Took the child to the Hospital ER. Was told child had a reaction. Given something for fever and med for rash. Mother did not know the name of medications. Stated she was on her way to work. States she was told to call the clinic and report the reaction.